Turning Point Therapeutics Inc. (TPTX) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
50 |
Employees |
111 |
Revenues (TTM) (Millions $) |
1 |
Net Income (TTM) (Millions $) |
-342 |
Cash Flow (TTM) (Millions $) |
-136 |
Capital Exp. (TTM) (Millions $) |
4 |
Turning Point Therapeutics Inc.
Turning Point Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel targeted cancer therapeutics for treating solid tumor malignancies. Founded in 2013 and headquartered in California, USA, the company is focused on developing small molecule inhibitors that selectively target specific genetic alterations and oncogenic pathways that are associated with cancer progression.
Turning Point Therapeutics is committed to transforming the way cancer is treated by developing drugs that are highly effective, safe, and well-tolerated. The company's lead drug candidate, repotrectinib, is currently being evaluated in multiple ongoing phase 1/2 clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and others.
In addition to repotrectinib, the company has a robust pipeline of other drug candidates that target various oncogenic pathways, including ALK, ROS1, and TRK fusion genes, which are frequently found in a range of cancer types. Turning Point Therapeutics aims to develop new drugs with improved clinical outcomes for cancer patients, as well as overcome resistance to current therapies.
The company has established collaborations with leading academic institutions, pharmaceutical companies, and contract research organizations (CROs) to advance the development and commercialization of its drugs. Turning Point Therapeutics has a highly experienced leadership team with a track record of success in drug development, clinical research, and commercialization.
Overall, Turning Point Therapeutics is a highly innovative biopharmaceutical company that is dedicated to improving the lives of cancer patients by developing targeted cancer therapeutics that address unmet medical needs. With a strong pipeline of drug candidates and a solid management team, the company is well-positioned for continued growth and success in the biopharmaceutical industry.
Company Address: 10628 Science Center Drive San Diego 92121 CA
Company Phone Number: 926-5251 Stock Exchange / Ticker: NASDAQ TPTX
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Neurogene Inc
Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment. Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.
|
Eyenovia Inc
Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future. 1. Co-Promotion Agreement with NovaBay Pharmaceuticals: Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.
|
Avenue Therapeutics Inc
Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition. Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Per Share |
Current |
Earnings (TTM) |
-6.9 $ |
Revenues (TTM) |
0.02 $
|
Cash Flow (TTM) |
- |
Cash |
16.46 $
|
Book Value |
15.96 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-6.9 $
|
Revenues (TTM) |
0.02 $ |
Cash Flow (TTM) |
- |
Cash |
16.46 $
|
Book Value |
15.96 $ |
Dividend (TTM) |
0 $ |
|
|
|
|